174 related articles for article (PubMed ID: 20235438)
1. Cannabis and Ecstasy/ MDMA: empirical measures of creativity in recreational users.
Jones KA; Blagrove M; Parrott AC
J Psychoactive Drugs; 2009 Dec; 41(4):323-9. PubMed ID: 20235438
[TBL] [Abstract][Full Text] [Related]
2. Is emotional intelligence impaired in ecstasy-polydrug users?
Craig L; Fisk JE; Montgomery C; Murphy PN; Wareing M
J Psychopharmacol; 2010 Feb; 24(2):221-31. PubMed ID: 18801831
[TBL] [Abstract][Full Text] [Related]
3. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms.
Milani RM; Parrott AC; Schifano F; Turner JJ
Hum Psychopharmacol; 2005 Jun; 20(4):249-61. PubMed ID: 15816011
[TBL] [Abstract][Full Text] [Related]
4. Evidence for executive deficits among users of MDMA (Ecstasy).
Fisk JE; Montgomery C; Murphy P; Wareing M
Br J Psychol; 2004 Nov; 95(Pt 4):457-66. PubMed ID: 15527532
[TBL] [Abstract][Full Text] [Related]
5. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
6. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
7. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.
Sumnall HR; Cole JC; Jerome L
J Psychopharmacol; 2006 Sep; 20(5):670-82. PubMed ID: 16401654
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?
Gouzoulis-Mayfrank E; Becker S; Pelz S; Tuchtenhagen F; Daumann J
Biol Psychiatry; 2002 May; 51(9):766-9. PubMed ID: 11983191
[TBL] [Abstract][Full Text] [Related]
9. Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use.
Butler GK; Montgomery AM
Drug Alcohol Depend; 2004 Oct; 76(1):55-62. PubMed ID: 15380289
[TBL] [Abstract][Full Text] [Related]
10. Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use.
Daumann J; Pelz S; Becker S; Tuchtenhagen F; Gouzoulis-Mayfrank E
Hum Psychopharmacol; 2001 Dec; 16(8):627-633. PubMed ID: 12404543
[TBL] [Abstract][Full Text] [Related]
11. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction.
Quednow BB; Jessen F; Kuhn KU; Maier W; Daum I; Wagner M
J Psychopharmacol; 2006 May; 20(3):373-84. PubMed ID: 16574711
[TBL] [Abstract][Full Text] [Related]
12. The relationships of 'ecstasy' (MDMA) and cannabis use to impaired executive inhibition and access to semantic long-term memory.
Murphy PN; Erwin PG; Maciver L; Fisk JE; Larkin D; Wareing M; Montgomery C; Hilton J; Tames FJ; Bradley B; Yanulevitch K; Ralley R
Hum Psychopharmacol; 2011 Oct; 26(7):460-9. PubMed ID: 21898599
[TBL] [Abstract][Full Text] [Related]
13. Impulsivity, inhibition and negative priming in ecstasy users.
Dafters RI
Addict Behav; 2006 Aug; 31(8):1436-41. PubMed ID: 16242244
[TBL] [Abstract][Full Text] [Related]
14. The relative contributions of ecstasy and cannabis to cognitive impairment.
Croft RJ; Mackay AJ; Mills AT; Gruzelier JG
Psychopharmacology (Berl); 2001 Jan; 153(3):373-9. PubMed ID: 11271410
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users.
Back-Madruga C; Boone KB; Chang L; Grob CS; Lee A; Nations H; Poland RE
Clin Neuropsychol; 2003 Nov; 17(4):446-59. PubMed ID: 15168910
[TBL] [Abstract][Full Text] [Related]
16. Self-reports of executive dysfunction in current ecstasy/polydrug Users.
Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
Cogn Behav Neurol; 2012 Sep; 25(3):128-38. PubMed ID: 22960437
[TBL] [Abstract][Full Text] [Related]
17. Development and initial validation of an MDMA/Ecstasy motives assessment.
Sottile JE; Macia KS; Wickham RE; Haug NA
Addict Behav; 2023 Jan; 136():107494. PubMed ID: 36162335
[TBL] [Abstract][Full Text] [Related]
18. Syllogistic reasoning performance in MDMA (Ecstasy) users.
Montgomery C; Fisk JE; Newcombe R; Wareing M; Murphy PN
Exp Clin Psychopharmacol; 2005 May; 13(2):137-45. PubMed ID: 15943546
[TBL] [Abstract][Full Text] [Related]
19. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
Morgan MJ; McFie L; Fleetwood H; Robinson JA
Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
[TBL] [Abstract][Full Text] [Related]
20. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
